First Time Loading...

Sorrento Therapeutics Inc
NASDAQ:SRNE

Watchlist Manager
Sorrento Therapeutics Inc Logo
Sorrento Therapeutics Inc
NASDAQ:SRNE
Watchlist
Price: 0.3322 USD 8.92%
Updated: Apr 30, 2024
Section:
 

Wall Street
Price Targets

SRNE Price Targets Summary
Sorrento Therapeutics Inc

There are no price targets for SRNE.
SRNE Lowest Forecast
Wall Street Target
Not Available
SRNE Average Forecast
Wall Street Target
Not Available
SRNE Highest Forecast
Wall Street Target
Not Available
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Sorrento Therapeutics Inc Competitors:
Price Targets
NGNE
Neurogene Inc
51% Upside
TSVT
2Seventy Bio Inc
144% Upside
LGND
Ligand Pharmaceuticals Inc
70% Upside
RXRX
Recursion Pharmaceuticals Inc
67% Upside
NGNE
Neurogene Inc
51% Upside
TSVT
2Seventy Bio Inc
144% Upside
LGND
Ligand Pharmaceuticals Inc
70% Upside
RXRX
Recursion Pharmaceuticals Inc
67% Upside
I
IVVD
Invivyd Inc
360% Upside
EXAI
Exscientia PLC
83% Upside
1672
Ascletis Pharma Inc
134% Upside
LVTX
LAVA Therapeutics NV
139% Upside

Revenue
Forecast

Revenue Estimate
Sorrento Therapeutics Inc

For the last 1 year the compound annual growth rate for Sorrento Therapeutics Inc's revenue is 19%. The projected CAGR for the next 1 year is -8%.

19%
Past Growth
-8%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Sorrento Therapeutics Inc

Operating Income forecast
is not available for
Sorrento Therapeutics Inc

Net Income
Forecast

Net Income Estimate
Sorrento Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

See Also

Summary
SRNE intrinsic value, competitors valuation, and company profile.
DCF Valuation
SRNE stock valuation using Discount Cash Flow valuation method.
Relative Valuation
SRNE stock valuation using valuation multiples.
Wall Street Estimates
SRNE price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
SRNE stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is SRNE's stock price target?
Not Available

SRNE doesn't have any price targets made by Wall Street professionals.

What is Sorrento Therapeutics Inc's Revenue forecast?
Projected CAGR
-8%

For the last 1 year the compound annual growth rate for Sorrento Therapeutics Inc's revenue is 19%. The projected CAGR for the next 1 year is -8%.

ALPHA SPREAD
Join more than 132,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.